Fig. 2: Predicted average plasma concentration-time profiles of different oral doses of olanzapine and their therapeutic-equivalent long-acting injectable (LAI) doses in pregnancy within one dosing interval at steady-state. | npj Women's Health

Fig. 2: Predicted average plasma concentration-time profiles of different oral doses of olanzapine and their therapeutic-equivalent long-acting injectable (LAI) doses in pregnancy within one dosing interval at steady-state.

From: Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics

Fig. 2

a 10 mg oral dose in the second trimester, b 10 mg oral dose in the third trimester, c 15 mg oral dose in the second trimester, d 15 mg oral dose in the third trimester, e 300 mg LAI dose in the second trimester, f 300 mg LAI dose in the third trimester, g 405 mg LAI dose in the second trimester, h 405 mg LAI in the third trimester. OLZ olanzapine, PO is oral, LAI is long-acting injectable, mAUC maternal area under the plasma concentration-time curve under one dosing interval, fAUC foetal area under the plasma concentration-time curve under one dosing interval, mCmax maternal maximum concentration at steady-state, fCmax foetal maximum concentration at steady state, fAUC/mAUC foetal to maternal AUC ratio.

Back to article page